Back to top
more

Oramed Pharmaceuticals Inc. (ORMP)

(Delayed Data from NSDQ)

$23.82 USD

23.82
934,761

+1.13 (4.98%)

Updated Sep 27, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (215 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

0 items in cart

Oramed Pharmaceuticals Inc. [ORMP]

Reports for Purchase

Showing records 1 - 20 ( 64 total )

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 1

09/21/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ORMP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 2

01/29/2021

Company Report

Pages: 5

Pipeline Advancing on Multiple Fronts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 3

01/22/2021

Company Report

Pages: 4

ORMD-0801 Phase 3 Program Patient Dosing Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 4

12/28/2020

Company Report

Pages: 5

Leptin Candidate Initial Clinical Data Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 5

11/25/2020

Company Report

Pages: 5

ORMD-0801 Global Phase 3 Program Patient Screening Begins; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 6

10/26/2020

Company Report

Pages: 5

Phase 3 Program Poised to Advance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 7

07/20/2020

Company Report

Pages: 4

Positive End-of-Phase 2 Meeting With FDA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 8

07/13/2020

Company Report

Pages: 4

F3Q20 Results Reported; Raising PT to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 9

06/22/2020

Company Report

Pages: 4

Initial Fatty Liver Trial Data; Reiterate Buy; Lowering PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 10

06/18/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 11

03/04/2020

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 12

01/07/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 13

09/18/2019

Company Report

Pages: 4

Last Patient Dosed in ORMD-0801 Phase 2b Trial; Top-Line Readout Next Month; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 14

07/22/2019

Company Report

Pages: 5

F3Q19 Financial Results Reported; Clinical Programs Advancing; Modulating Target to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 15

06/25/2019

Company Report

Pages: 6

Price: 24.95

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 16

06/19/2019

Company Report

Pages: 5

Multiple Clinical Data Catalysts Near-Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 17

05/23/2019

Company Report

Pages: 4

Phase 2b Trial Enrollment Completed; Top-Line Data in 4Q19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 18

05/23/2019

Company Report

Pages: 4

Phase 2b Trial Enrollment Completed; Top-Line Data in 4Q19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 19

05/07/2019

Company Report

Pages: 7

Price: 24.95

Company: Oramed Pharmaceuticals Inc.

Industry: Medical - Products

Record: 20

04/15/2019

Company Report

Pages: 4

F1Q19 Financial Results Reported; Oral Exenatide Patent Allowed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party